. 2020 Dec 20;28(3):454–463. doi: 10.1111/jvh.13456

TABLE 2.

Pooled results from the treatment efficacy

	RVR n (%)	SVR n (%)	Relapse n (%)	Non‐response n (%)
Reduction of immunosuppressive medication (21 studies, 174 patients)	N/A	55 (32)	N/A	119 (68)
Ribavirin (34 studies, 395 patients)	99 (25)	301 (76)	73 (18)	22 (6)
Pegylated interferon‐α (8 studies, 13 patients)	4 (31)	11 (84)	1 (8)	1 (8)

RVR

n (%)

SVR

n (%)

Relapse

n (%)

Non‐response

n (%)

Reduction of immunosuppressive medication (21 studies, 174 patients)

N/A

55 (32)

N/A

119 (68)

Ribavirin (34 studies, 395 patients)

99 (25)

301 (76)

73 (18)

22 (6)

Pegylated interferon‐α (8 studies, 13 patients)

4 (31)

11 (84)

1 (8)

Abbreviations: RVR; rapid virological response (undetectable HEV RNA within one month after start of treatment); SVR, sustained virological response (undetectable HEV RNA for at least 3 months after cessation of therapy); Relapse, relapse of HEV RNA in serum and/or stool within 3 months after cessation of therapy; Non‐responder, serum HEV RNA remains positive during and after cessation of treatment.